High prevalence of coronary artery calcification and increased risk for coronary artery disease in patients with Sheehan syndrome—A case–control study

Patients with Sheehan syndrome (SS) are predisposed to coronary artery disease (CAD) due to risk factors like abdominal obesity, dyslipidemia and chronic inflammation. In addition to estimate CAD risk enhancers like high sensitive C reactive protein (hsCRP), apolipoprotein B (ApoB) and lipoprotein A [Lp(a)], this study applies Framingham risk score (FRS) and coronary artery calcium (CAC) score to compute a 10‐year probability of cardiovascular (CV) events in SS patients.

[1]  A. Zargar,et al.  Prevalence of coronary calcium deposits in Sheehan’s syndrome patients on long term replacement treatment , 2021, Pituitary.

[2]  R. McClelland,et al.  Lipoprotein (a) and Coronary Artery Calcification: Prospective study assessing interactions with other risk factors. , 2021, Metabolism: clinical and experimental.

[3]  M. Nöthen,et al.  Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification , 2020, BMC Medical Genetics.

[4]  R. M. Jales,et al.  Panhypopituitarism Without GH Replacement: About Insulin Sensitivity, CRP Levels, and Metabolic Syndrome , 2018, Hormone and Metabolic Research.

[5]  B. Laway,et al.  Serum Lipid and Leptin Concentrations in Patients with Sheehan Syndrome , 2018, Indian journal of endocrinology and metabolism.

[6]  Fares Alahdab,et al.  Mortality in adults with hypopituitarism: a systematic review and meta-analysis , 2017, Endocrine.

[7]  T. Lehtimäki,et al.  Life-course risk factor levels and coronary artery calcification. The Cardiovascular Risk in Young Finns Study. , 2016, International journal of cardiology.

[8]  R. Kronmal,et al.  Improving the CAC Score by Addition of Regional Measures of Calcium Distribution: Multi-Ethnic Study of Atherosclerosis. , 2016, JACC. Cardiovascular imaging.

[9]  M. Murad,et al.  Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[10]  B. Laway,et al.  Clinical, hormonal and radiological features of partial Sheehan's syndrome: an Indian experience. , 2016, Archives of endocrinology and metabolism.

[11]  R. Kronmal,et al.  10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). , 2015, Journal of the American College of Cardiology.

[12]  M. Bhat,et al.  Insulin resistance, metabolic syndrome and chronic low grade inflammation in Sheehan’s syndrome on standard replacement therapy: a case control study , 2015, Pituitary.

[13]  K. Sung,et al.  HDL-C levels modify the association between C-reactive protein and coronary artery calcium score. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[14]  M. Budoff,et al.  Comparing coronary artery calcium among U.S. South Asians with four racial/ethnic groups: the MASALA and MESA studies. , 2014, Atherosclerosis.

[15]  C. Becker,et al.  Lipoprotein (a) is independently correlated with coronary artery calcification. , 2013, European journal of internal medicine.

[16]  M. Thunander,et al.  Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. , 2011, European journal of endocrinology.

[17]  A. Zargar,et al.  Selective preservation of anterior pituitary functions in patients with Sheehan's syndrome , 2011, Indian journal of endocrinology and metabolism.

[18]  N John Bosomworth,et al.  Practical use of the Framingham risk score in primary prevention: Canadian perspective. , 2011, Canadian family physician Medecin de famille canadien.

[19]  A. Alibrandi,et al.  High prevalence of coronary calcifications and increased risk for coronary heart disease in adults with growth hormone deficiency. , 2011, Journal of endocrinological investigation.

[20]  O. Ayyıldız,et al.  Analysis of thrombophilic genetic mutations in patients with Sheehan`s syndrome: is thrombophilia responsible for the pathogenesis of Sheehan`s syndrome? , 2011, Pituitary.

[21]  A. Zargar,et al.  Prevalence of hematological abnormalities in patients with Sheehan’s syndrome: response to replacement of glucocorticoids and thyroxine , 2011, Pituitary.

[22]  Klaus Mann,et al.  Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. , 2010, Journal of the American College of Cardiology.

[23]  P. Greenland,et al.  Coronary artery calcium score and risk classification for coronary heart disease prediction. , 2010, JAMA.

[24]  R. Clayton,et al.  ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[25]  Moyses Szklo,et al.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups. , 2008, The New England journal of medicine.

[26]  David M Herrington,et al.  Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). , 2007, Archives of internal medicine.

[27]  C. Coeli,et al.  Two years of growth hormone replacement therapy in a group of patients with Sheehan’s syndrome , 2006, Pituitary.

[28]  F. Keleştimur,et al.  Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database. , 2005, European journal of endocrinology.

[29]  F. Crea,et al.  Insulin-Like Growth Factor-1 as a Vascular Protective Factor , 2004, Circulation.

[30]  Michael Pignone,et al.  Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. , 2004, Archives of internal medicine.

[31]  P. Chanson,et al.  Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. , 2004, The Journal of clinical endocrinology and metabolism.

[32]  M. Reiser,et al.  CT measurement of coronary calcium mass: impact on global cardiac risk assessment , 2004, European Radiology.

[33]  Kiang Liu,et al.  Electron-Beam Tomography Coronary Artery Calcium and Cardiac Events: A 37-Month Follow-Up of 5635 Initially Asymptomatic Low- to Intermediate-Risk Adults , 2003, Circulation.

[34]  K. Kovács.  Sheehan syndrome , 2003, The Lancet.

[35]  J. Wikstrand,et al.  Intima‐media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors , 2002, Clinical endocrinology.

[36]  R. Clayton,et al.  Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities , 2001, Clinical endocrinology.

[37]  L. Hagmar,et al.  Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. , 2000, The Journal of clinical endocrinology and metabolism.

[38]  A. Netter,et al.  [Sheehan's syndrome]. , 1951, Gazette medicale de France.